Mitchell Nides

Summary

Publications

  1. ncbi Update on pharmacologic options for smoking cessation treatment
    Mitchell Nides
    Los Angeles Clinical Trials, Los Angeles, California 91505, USA
    Am J Med 121:S20-31. 2008
  2. ncbi Pharmacokinetics, safety and efficacy from randomized controlled trials of 1 and 2 mg nicotine bitartrate lozenges (Nicotinell)
    Bertrand Dautzenberg
    Novartis Santé Familiale, Rueil Malmaison, France
    BMC Clin Pharmacol 7:11. 2007
  3. ncbi Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis
    Mitchell Nides
    Los Angeles Clinical Trials, 4116 W Magnolia Boulevard, Burbank, CA 91505, USA
    Am J Health Behav 32:664-75. 2008
  4. ncbi Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up
    Mitchell Nides
    Los Angeles Clinical Trials, 2990 S Sepulveda Boulevard, Los Angeles, CA 90064, USA
    Arch Intern Med 166:1561-8. 2006
  5. ncbi Maximizing smoking cessation in clinical practice: pharmacologic and behavioral interventions
    Mitchell Nides
    Los Angeles Clinical Trails, Los Angeles, CA 90025, USA
    Prev Cardiol 10:23-30. 2007
  6. ncbi Hollywood quits--behind the scenes of a Hollywood-based smoking cessation program
    Mitchell Nides
    Los Angeles Clinical Trials, Burbank, CA 91505, USA trials com
    Am J Health Behav 31:705-18. 2007
  7. ncbi Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation
    Cheryl Oncken
    University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030, USA
    Arch Intern Med 166:1571-7. 2006
  8. ncbi Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial
    David Gonzales
    Smoking Cessation Center, Department of Medicine, Oregon Health and Science University, Portland, OR 97239, USA
    JAMA 296:47-55. 2006
  9. ncbi Comparative testing of 5 nicotine systems: initial use and preferences
    Nina G Schneider
    Nicotine Dependence Research Unit, Greater Los Angeles Veterans Administration, West Los Angeles, CA 90073, USA
    Am J Health Behav 28:72-86. 2004
  10. ncbi Smoking reduction in the Lung Health Study
    John Hughes
    Departments of Psychiatry, Psychology and Family Practice, University of Vermont, Burlington, VT 05401 1419, USA
    Nicotine Tob Res 6:275-80. 2004

Detail Information

Publications10

  1. ncbi Update on pharmacologic options for smoking cessation treatment
    Mitchell Nides
    Los Angeles Clinical Trials, Los Angeles, California 91505, USA
    Am J Med 121:S20-31. 2008
    ..Ultimately, selection of pharmacologic agent should be based on the patient's comorbidities and preferences, as well as on the agent's adverse event profile...
  2. ncbi Pharmacokinetics, safety and efficacy from randomized controlled trials of 1 and 2 mg nicotine bitartrate lozenges (Nicotinell)
    Bertrand Dautzenberg
    Novartis Santé Familiale, Rueil Malmaison, France
    BMC Clin Pharmacol 7:11. 2007
    ....
  3. ncbi Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis
    Mitchell Nides
    Los Angeles Clinical Trials, 4116 W Magnolia Boulevard, Burbank, CA 91505, USA
    Am J Health Behav 32:664-75. 2008
    ....
  4. ncbi Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up
    Mitchell Nides
    Los Angeles Clinical Trials, 2990 S Sepulveda Boulevard, Los Angeles, CA 90064, USA
    Arch Intern Med 166:1561-8. 2006
    ..This study evaluated the efficacy, tolerability, and safety of 3 varenicline doses for smoking cessation. Bupropion hydrochloride was included as an active control...
  5. ncbi Maximizing smoking cessation in clinical practice: pharmacologic and behavioral interventions
    Mitchell Nides
    Los Angeles Clinical Trails, Los Angeles, CA 90025, USA
    Prev Cardiol 10:23-30. 2007
    ....
  6. ncbi Hollywood quits--behind the scenes of a Hollywood-based smoking cessation program
    Mitchell Nides
    Los Angeles Clinical Trials, Burbank, CA 91505, USA trials com
    Am J Health Behav 31:705-18. 2007
    ..To develop, implement, and assess the efficacy of a comprehensive, evidence-based smoking cessation program for entertainment industry workers and their families...
  7. ncbi Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation
    Cheryl Oncken
    University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030, USA
    Arch Intern Med 166:1571-7. 2006
    ....
  8. ncbi Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial
    David Gonzales
    Smoking Cessation Center, Department of Medicine, Oregon Health and Science University, Portland, OR 97239, USA
    JAMA 296:47-55. 2006
    ..TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00141206...
  9. ncbi Comparative testing of 5 nicotine systems: initial use and preferences
    Nina G Schneider
    Nicotine Dependence Research Unit, Greater Los Angeles Veterans Administration, West Los Angeles, CA 90073, USA
    Am J Health Behav 28:72-86. 2004
    ..To test initial reactions to 5 nicotine treatments (NRTs: 2 and 4 mg gum, inhaler, nasal spray, tablet) in a crossover study (n=41)...
  10. ncbi Smoking reduction in the Lung Health Study
    John Hughes
    Departments of Psychiatry, Psychology and Family Practice, University of Vermont, Burlington, VT 05401 1419, USA
    Nicotine Tob Res 6:275-80. 2004
    ..We conclude that reduction can be maintained but such reduction neither predicts an increased nor decreased probability of future cessation...